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Yellow fever in Paraguay
The latest report concerning the outbreak of Yellow fever in Paraguay, dated 15 March 2008, stated that a total of 24 confirmed cases had been
reported by the Ministry of Public Health and Social Welfare (ProMED-mail archive number 20080315.1029). The most recent suspected case
was reported on 6 March 2008. In total, eight patients had died. Three departments were affected by the infection: San Pedro (13 out of the
24 cases), Central (10/24), and Caaguazu (1/24).
Over 1.4 million doses of yellow fever vaccine have already been administered in priority districts in Paraguay. Vaccination coverage in the
various departments is highly variable: San Estanislao 92.9%; Guayaibi 37.6%; Iribucua 91.6%; Lima 99.4%; San Lorenzo 52.9% and Caaguazu 11%.
Of interest, 171 adverse effects to the vaccine have been reported: 134 were classified as intermediate, 10 moderate, 5 serious (3 encephalitis
and 2 Guillain-Barre), 15 were under investigation, and 7 had been discarded.
In Paraguay, authorities have been focussing on trying to reduce the population of mosquitoes by fumigating areas with a higher risk of
transmission, and attempting to eliminate breeding sites for themosquitoes. Residents were being advised to cover water storage tanks, empty
and upend any unused containers, and clean up discarded plastic food containers, used car tires and other items that could collect small pools
of rainwater where mosquitoes can lay their eggs.
This is the first outbreak of Yellow fever in Paraguay since 1974. As a result, the World Health Organisation (WHO) is now recommending yellow
fever vaccination for all travelers entering Paraguay (http://www.who.int/ith/en/index.html).
XDR-TB in Scotland, ex Somalia
Following on from the ProMED update about XDR-TB in Botswana in the last issue of this journal, on 22 March 2008 ProMED-mail reported a case
of extensively drug-resistant tuberculosis (XDR-TB) in Scotland (ProMED-mail archive number 20080322.1094). This is thought to be the first
case reported in the UK since the revised definition of XDR-TB was published by the WHO in 2006. It seems that an earlier case in the UK in 2003
was only retrospectively identified as XDR-TB.
Initial information about the recent Scottish case described a Somali male in his 30s who arrived in the UK in November 2007. When he was
screened for infectious diseases at Heathrow airport, TB scars were seen on chest X-rays, and the disease was thought to be inactive. The
patient told doctors he had recently taken a six-month course of treatment for TB, and he was allowed to travel to Scotland following an
immigration interview. In January 2008 he was admitted to Gartnavel General Hospital in Glasgow following reactivation of pulmonary TB, and
cultures later revealed the XDR strain. XDR-TB is resistant to both 1st line (isoniazid and rifampin) and 2nd line drugs (fluoroquinolones, and at
least one of the three injectable anti-tuberculosis drugs capreomycin, kanamycin, and amikacin).
As discussed on ProMED-mail, this Somali patient probably had XDR-TB to begin with (ProMED-mail archive number 20080322.1094). The exact
components of his six-month regimen are not stated, but should have included isoniazid, rifampicin, pyrazinamide and ethambutol. This six-
month regimen is only designed to treat drug-susceptible strains of Mycobacterium tuberculosis (MTB), although initial resistance to isoniazid
does not compromise the outcome for this 4-drug regimen. However, initial resistance to rifampicin does compromise the outcome, and
susceptibility to pyrazinamide is also essential for the six-month regimen to be effective.
The ProMED-mail commentary suggests the patient was given the six-month regimen inappropriately, in the absence of drug-susceptibility
testing, and was mistakenly assumed to have inactive disease when he entered the UK in November 2007. It is unlikely that he developed XDR-
TB as a result of non-adherence to the six-month regimen, when he relapsed only 2 months later. Such non-adherence would not easily explain
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acquisition of resistance to the fluoroquinolones and at least one of the drugs capreomycin, kanamycin, and amikacin. Development of XDR-TB
usually follows the inappropriate use of these 2nd-line drugs in a patient for whom 1st-line drugs are failing.
As pointed out previously (ProMED-mail archive number 20080228.0813) a recent study (Pillay M, Sturm AW. Clin Infect Dis. 2007; 45: 1409-14)
postulated that the introduction of the 6-month directly observed therapy-based tuberculosis-controlprogrammes in the absence of
susceptibility testing or drug resistance surveillance was instrumental in the development of XDR in a highly transmissible strain in KwaZulu
Natal, South Africa.
Murray Valley Encephalitis Virus in Australia (State of Victoria)
Murray Valley Encephalitis virus, which has its reservoir in water birds and is spread bymosquitoes, has been detected in a sentinel chicken flock
in northern Victoria. Victoria is located in southeastern Australia. Thus far there have not been any human cases of the illness. Its transmission
by mosquitoes is most often by Culex annulirostris, which is also known as the ‘‘common banded’’ mosquito.
According to the State Government of Victoria website (http://www.health.vic.gov.au/ideas/bluebook/murrayvalley):
Murray Valley Encephalitis virus is endemic in northern Australia and Papua New Guinea where sporadic cases or small
outbreaks of Murray Valley Encephalitis virus encephalitis occur every few years. This is usually at the end of the wet season.
Seven outbreaks of Murray Valley Encephalitis virus encephalitis have occurred at irregular intervals in southeastern
Australia since 1917. The last of these was in 1974. During these times there was heavy rainfall leading to widespread
flooding which promoted large increases in water bird and vector mosquito populations. The Murray Valley Encephalitis virus
numbers were amplified in the bird-mosquito-bird cycle and humans became infected when bitten by mosquitoes carrying
the virus.
Murray Valley Encephalitis virus is, like Kunjin virus (another viral cause of encephalitis in Australia), a flavivirus. It is also related to such other
flaviviruses as Japanese encephalitis virus, West Nile virus, and St. Louis encephalitis virus.
On the basis of serologic testing in the setting of outbreaks of Murray Valley Encephalitis virus only 1 out of every 800 people who are infected
with the virus actually develop clinical illness.
After an incubation period of 7 to 28 days, Murray Valley Encephalitis virus may cause ‘‘a comparatively mild disease with features such as
fever, headache, nausea and vomiting. In a small percentage of all people infected, mild diseasemay be a prodrome to disease progression and
involvement of the central nervous system. This can result in meningitis or encephalitis of variable severity. Signs of brain dysfunction such as
drowsiness, confusion, fitting, weakness or ataxia indicate the onset of encephalitis. Of those presenting with encephalitis in Victoria in the
1974 epidemic, approximately one-third died, one-third were left with residual brain damage and one-third recovered completely’’ according
to the State Government of Victoria website (http://www.health.vic.gov.au/ideas/bluebook/murrayvalley).
In addition to efforts at increasing the awareness of local health care providers, people who live in the area have been advised as to how to
prevent mosquito bites.
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